{
    "@context": "https://schema.org/",
    "@type": "Dataset",
    "_id": "sdy3050",
    "_score": 10.858765,
    "abstract": "Evaluation of COBRA HA and NA vaccine in pre-immune mice after virus challenge to identify differences in antibody secreting cells, serological response and lung damage.",
    "author": [
        {
            "@type": "Person",
            "affiliation": {
                "name": "Other: Cleveland Clinic"
            },
            "name": "Ted Ross"
        }
    ],
    "citedBy": [
        {
            "@type": "ScholarlyArticle",
            "doi": "10.3390/vaccines12070706",
            "name": "A Computationally Optimized Broadly Reactive Hemagglutinin and Neuraminidase Vaccine Boosts Antibody-Secreting Cells and Induces a Robust Serological Response, Preventing Lung Damage in a Pre-Immune Model.",
            "pmid": "39066344",
            "url": "https://pubmed.ncbi.nlm.nih.gov/39066344"
        }
    ],
    "conditionsOfAccess": "Closed",
    "curatedBy": {
        "@type": "Organization",
        "name": "ImmPort Data Curation Team"
    },
    "date": "2025-04-24",
    "dateModified": "2025-04-24T00:00:00",
    "description": "Healthy mice were pre-immunized and vaccinated with COBRA vaccine containing H2, H5, H7, N1 and N2 antigens. The mice were then challenged with A/Hong Kong/125/2017/H7N9 virus. Samples were collected to assess protective efficacy and immune response.",
    "distribution": [
        {
            "@type": "DataDownload",
            "contentUrl": "https://browser.immport.org/browser?path=SDY3050",
            "dateModified": "2025-04-24T00:00:00",
            "encodingFormat": "URL"
        }
    ],
    "doi": "10.21430/M30BOPS0TE",
    "funding": [
        {
            "endDate": "2020-09-09",
            "funder": [
                {
                    "alternateName": [
                        "National Institute of Allergy & Infectious Diseases",
                        "NIAID",
                        "Instituto Nacional de Alergias y Enfermedades Infecciosas"
                    ],
                    "identifier": "https://ror.org/043z4tv69",
                    "name": "National Institute of Allergy and Infectious Diseases",
                    "parentOrganization": "National Institutes of Health"
                }
            ],
            "identifier": "75N93019C00052-0-9999-1",
            "name": "CIVIC: University of Georgia Center for Influenza Vaccine Research in High Risk Populations",
            "startDate": "2019-09-10",
            "url": "https://reporter.nih.gov/project-details/10021763"
        },
        {
            "funder": {
                "@type": "Organization",
                "alternateName": [
                    "National Institute of Allergy & Infectious Diseases",
                    "NIAID",
                    "Instituto Nacional de Alergias y Enfermedades Infecciosas"
                ],
                "identifier": "https://ror.org/043z4tv69",
                "name": "National Institute of Allergy and Infectious Diseases",
                "parentOrganization": "National Institutes of Health"
            }
        }
    ],
    "healthCondition": [
        {
            "alternateName": [
                "influenza with non-respiratory manifestation",
                "orthomyxoviridae caused disease or disorder",
                "Influenza with other manifestations",
                "orthomyxoviridae disease or disorder",
                "flu",
                "influenza infection",
                "orthomyxoviridae infectious disease"
            ],
            "identifier": "0005812",
            "inDefinedTermSet": "MONDO",
            "isCurated": true,
            "name": "influenza",
            "originalName": "influenza",
            "url": "http://purl.obolibrary.org/obo/MONDO_0005812"
        }
    ],
    "identifier": [
        "10.21430/M30BOPS0TE"
    ],
    "includedInDataCatalog": {
        "@type": "DataCatalog",
        "archivedAt": "https://immport.org/shared/study/SDY3050",
        "name": "ImmPort",
        "url": "https://immport.org",
        "versionDate": "2025-04-24T00:00:00"
    },
    "isAccessibleForFree": true,
    "isBasedOn": [
        {
            "additionalType": {
                "name": "Experiment"
            },
            "description": "Preimmunized with Influenza Viruses",
            "identifier": "PTL12298",
            "name": "05 FER-000 Standardization in Ferret Procedures.pdf",
            "url": "https://www.immport.org/browser/?path=SDY3050"
        }
    ],
    "keywords": [
        "CIVICs Collaborative Influenza Vaccine Innovation Centers",
        "Immunogenicity will be determined by HAI and ELISA serum antibody titers, spleenocyte ASCs against panels of historical, co-circulating, and future drifted H2Nx, H5Nx, H7Nx influenza viruses."
    ],
    "license": "https://www.immport.org/agreement",
    "measurementTechnique": [
        {
            "name": "ELISPOT"
        },
        {
            "name": "Virus Plaque Assay"
        },
        {
            "name": "ELISA"
        },
        {
            "name": "Hemagglutination Inhibition"
        }
    ],
    "name": "COBRA HA and NA vaccine boosts antibody-secreting cells and induces serological response.",
    "sameAs": "https://doi.org/10.21430/M30BOPS0TE",
    "sourceOrganization": [
        {
            "@type": "ResearchProject",
            "abstract": "Collaborative Influenza Vaccine Innovation Centers (CIVICs) is a network of research centers working collaboratively to develop next-generation influenza vaccines. Their goal is to create vaccines that provide broader, longer-lasting protection against influenza viruses.",
            "alternateName": [
                "CIVIC",
                "Collaborative Influenza Vaccine Innovation Centers",
                "CIVICs"
            ],
            "correctionApproved": true,
            "description": "Collaborative Influenza Vaccine Innovation Centers (CIVICs) is a network of research centers that will work together in a coordinated, multidisciplinary effort to develop more durable, broadly protective and longer-lasting influenza vaccines. For more information, visit the NIAID program page: https://www.niaid.nih.gov/research/civics",
            "name": "NIAID CIVICs Network",
            "parentOrganization": [
                "NIAID"
            ],
            "url": "https://www.niaidcivics.org/"
        }
    ],
    "species": [
        {
            "alternateName": [
                "Mouse",
                "LK3 transgenic mice",
                "Mus musculus Linnaeus, 1758",
                "Mus sp. 129SV",
                "house mouse",
                "mice C57BL/6xCBA/CaJ hybrid",
                "mouse",
                "nude mice",
                "transgenic mice"
            ],
            "classification": "host",
            "commonName": "Mouse",
            "curatedBy": {
                "dateModified": "2023-10-05",
                "name": "PubTator",
                "url": "https://www.ncbi.nlm.nih.gov/research/pubtator/api.html"
            },
            "displayName": "Mouse | Mus musculus",
            "identifier": "10090",
            "inDefinedTermSet": "UniProt",
            "isCurated": true,
            "name": "Mus musculus",
            "originalName": "mus musculus",
            "url": "https://www.uniprot.org/taxonomy/10090"
        }
    ],
    "url": "https://immport.org/shared/study/SDY3050"
}